Mouse Models for Immunotherapy in Hepatocellular Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Nov 17

PMID 31731753

Citations 18

Authors

Enya Li

Li Lin

Chia-Wei Chen

Da-Liang Ou

Affiliations

Soon will be listed here.

Abstract

Liver cancer is one of the dominant causes of cancer-related mortality, and the survival rate of liver cancer is among the lowest for all cancers. Immunotherapy for hepatocellular carcinoma (HCC) has yielded some encouraging results, but the percentage of patients responding to single-agent therapies remains low. Therefore, potential directions for improved immunotherapies include identifying new immune targets and checkpoints and customizing treatment procedures for individual patients. The development of combination therapies for HCC is also crucial and urgent and, thus, further studies are required. Mice have been utilized in immunotherapy research due to several advantages, for example, being low in cost, having high success rates for inducing tumor growth, and so on. Moreover, immune-competent mice are used in immunotherapy research to clarify the role that the immune system plays in cancer growth. In this review paper, the advantages and disadvantages of mouse models for immunotherapy, the equipment that are used for monitoring HCC, and the cell strains used for inducing HCC are reviewed.

Citing Articles

Hypoxic tumor cell line lysate-pulsed dendritic cell vaccine exhibits better therapeutic effects on hepatocellular carcinoma.

Jeng L, Shih F, Liao Y, Shyu W, Teng C Br J Cancer. 2025; .

PMID: 40050434 DOI: 10.1038/s41416-025-02975-w.

Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors.

Nipper A, Warren E, Liao K, Liu H, Michikawa C, Porter C Immunohorizons. 2024; 8(8):598-605.

PMID: 39225630 PMC: 11374747. DOI: 10.4049/immunohorizons.2400059.

Establishment of humanised xenograft models as study for lung metastasis of osteosarcoma.

Khamarudin F, Muhamad M, Johari Ibahim M, Wan Mohamad Zain W, Aziz M, Adib Ridzuan N Immunother Adv. 2024; 4(1):ltae002.

PMID: 38826586 PMC: 11143482. DOI: 10.1093/immadv/ltae002.

Animal model considerations for chordoma research: reproducing the tumor microenvironment with humanized mice.

Campilan B, Schroeder C, Sagaityte E, Arditi J, Leary O, Ziya L Gokaslan Front Oncol. 2024; 14:1330254.

PMID: 38544830 PMC: 10965562. DOI: 10.3389/fonc.2024.1330254.

Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.

Jang J, Lee B, Huang M, Seo C, Choi J, Shin Y Mol Oncol. 2024; 18(8):1923-1939.

PMID: 38511232 PMC: 11306519. DOI: 10.1002/1878-0261.13633.

References

Heindryckx F, Colle I, Van Vlierberghe H . Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009; 90(4):367-86. PMC: 2741148. DOI: 10.1111/j.1365-2613.2009.00656.x. View

Liu Y, Tseng T, Soong R, Peng C, Cheng Y, Huang S . A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment. J Immunother Cancer. 2018; 6(1):144. PMC: 6286542. DOI: 10.1186/s40425-018-0462-3. View

Ou D, Lin Y, Hsu C, Lin Y, Chen C, Yu J . Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer. 2019; 8(3):155-171. PMC: 6547269. DOI: 10.1159/000489318. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

Yamagiwa K, Ichikawa K . Experimental study of the pathogenesis of carcinoma. CA Cancer J Clin. 1977; 27(3):174-81. DOI: 10.3322/canjclin.27.3.174. View

Li G, Liu D, Kimchi E, Kaifi J, Qi X, Manjunath Y . Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018; 154(4):1024-1036.e9. PMC: 5908238. DOI: 10.1053/j.gastro.2017.10.050. View

Reiberger T, Chen Y, Ramjiawan R, Hato T, Fan C, Samuel R . An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc. 2015; 10(8):1264-74. PMC: 4800979. DOI: 10.1038/nprot.2015.080. View

DuPage M, Jacks T . Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol. 2013; 25(2):192-9. PMC: 3910114. DOI: 10.1016/j.coi.2013.02.005. View

Li S, Hsu D, Li B, Luo X, Alderson N, Qiao L . Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab. 2014; 20(2):320-32. PMC: 4365973. DOI: 10.1016/j.cmet.2014.05.020. View

10.

Holzapfel B, Wagner F, Thibaudeau L, Levesque J, Hutmacher D . Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. Stem Cells. 2015; 33(6):1696-704. DOI: 10.1002/stem.1978. View

11.

Shen J, Tsoi H, Liang Q, Chu E, Liu D, Yu A . Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma. Oncogene. 2016; 35(49):6271-6280. PMC: 5153568. DOI: 10.1038/onc.2016.162. View

12.

Wang Q, Yu W, Chen X, Peng X, Jeon S, Birnbaum M . Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. Cancer Cell. 2016; 29(4):523-535. PMC: 4921241. DOI: 10.1016/j.ccell.2016.02.008. View

13.

Laparra J, Fotschki B, Haros C . Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model. Oncotarget. 2019; 10(7):760-772. PMC: 6366820. DOI: 10.18632/oncotarget.26605. View

14.

Zong L, Peng H, Sun C, Li F, Zheng M, Chen Y . Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. Nat Commun. 2019; 10(1):221. PMC: 6333806. DOI: 10.1038/s41467-018-08096-8. View

15.

Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M . Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. J Immunother Cancer. 2018; 6(1):125. PMC: 6247677. DOI: 10.1186/s40425-018-0431-x. View

16.

Ou D, Chang C, Jeng Y, Lin Y, Lin Z, Gandhi A . Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. J Gastroenterol Hepatol. 2014; 29(12):2021-31. DOI: 10.1111/jgh.12708. View

17.

Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin S . From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2014; 2(3-4):367-83. PMC: 3881319. DOI: 10.1159/000343852. View

18.

Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan J . TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem. 2015; 35(4):1623-32. DOI: 10.1159/000373976. View

19.

Keng V, Tschida B, Bell J, Largaespada D . Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. Hepatology. 2011; 53(3):781-90. PMC: 3079950. DOI: 10.1002/hep.24091. View

20.

Chung S, Moon H, Kim D, Cho K, Ju H, Kim D . Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterol. 2016; 16:13. PMC: 4731926. DOI: 10.1186/s12876-016-0423-6. View